CG Oncology Inc. has announced an expedited timeline for the topline data readout of its Phase 3 PIVOT-006 clinical trial. The study evaluates adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC). Topline data from this randomized, open-label registrational trial are now expected in the first half of 2026, nearly one year ahead of schedule due to rapid enrollment across more than 90 sites. The results have not yet been presented and will be available in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622702-en) on January 09, 2026, and is solely responsible for the information contained therein.